2invest AG
SYGNIS AG announces outcome of Annual General Meeting 2016
DGAP-News: SYGNIS AG / Key word(s): AGM/EGM Press Release
SYGNIS AG announces outcome of Annual General Meeting 2016
Madrid, Spain and Heidelberg, Germany, 20 June 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announced today that the Annual General Meeting (AGM) held in Wiesloch today on 20 June 2016 voted in favour of all Management proposals put to vote. Participating shareholders representing 44 percent of the entire share capital of 16.8 million shares approved all proposals of the Management with a large majority. The main decision was related to the planned acquisition of Expedeon Holdings Ltd. that was announced on 9 May 2016. To finance the transaction, the AGM approved that the Company’s share capital will be increased by up to EUR 20,538,089.00 from EUR 16,803,891.00 to EUR 37,341,980.00 by issuing up to 20,538,089 shares by way of a rights offering. In addition, the AGM approved that Tim McCarthy and Trevor Jarman, previously member of the Board of Directors, respectively Chairman of the Board of Directors of Expedeon, were appointed as new Supervisory Board members of SYGNIS, while Friedrich von Bohlen und Halbach, PhD, and Pedro-Agustín del Castillo Machado have left the Supervisory Board; Chairwoman Cristina Garmendia Mendizábal thanked them for their collaboration during the last years. Further decisions at the AGM were the discharge of the members of the Supervisory and the Management Board for the past fiscal year, the creation of new authorized capital, as well as changes due to the authorization the Management Board to issue convertible bonds, excluding subscription rights, among others. For further information please contact:
SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime(TM) product line and SensiPhi(R), licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript(TM) Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03). ### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
2016-06-20 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | SYGNIS AG | |
Waldhofer Str. 104 | ||
69123 Heidelberg | ||
Germany | ||
Phone: | +49 (0) 6221 3540 125 | |
Fax: | +49 (0) 6221 3540 127 | |
E-mail: | investors@sygnis.com | |
Internet: | www.sygnis.com | |
ISIN: | DE000A1RFM03 | |
WKN: | A1RFM0 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |